Syon Capital LLC Makes New Investment in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Syon Capital LLC purchased a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 15,546 shares of the company's stock, valued at approximately $287,000. Syon Capital LLC owned approximately 0.05% of Fulgent Genetics as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. GAMMA Investing LLC grew its stake in shares of Fulgent Genetics by 45.5% in the 4th quarter. GAMMA Investing LLC now owns 2,133 shares of the company's stock valued at $39,000 after buying an additional 667 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in shares of Fulgent Genetics by 5.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 35,324 shares of the company's stock valued at $652,000 after buying an additional 1,689 shares in the last quarter. Federated Hermes Inc. grew its stake in shares of Fulgent Genetics by 4.4% in the 4th quarter. Federated Hermes Inc. now owns 41,882 shares of the company's stock valued at $774,000 after buying an additional 1,774 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of Fulgent Genetics by 267.4% in the 4th quarter. Russell Investments Group Ltd. now owns 2,693 shares of the company's stock valued at $50,000 after buying an additional 1,960 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd grew its stake in shares of Fulgent Genetics by 15.2% in the 4th quarter. Dynamic Technology Lab Private Ltd now owns 15,129 shares of the company's stock valued at $280,000 after buying an additional 1,995 shares in the last quarter. Institutional investors own 48.06% of the company's stock.

Fulgent Genetics Stock Performance

Shares of FLGT traded down $0.24 during mid-day trading on Thursday, hitting $17.12. The company's stock had a trading volume of 187,587 shares, compared to its average volume of 261,881. Fulgent Genetics, Inc. has a one year low of $14.57 and a one year high of $25.11. The firm has a market capitalization of $528.27 million, a PE ratio of -3.10 and a beta of 1.36. The stock's 50-day moving average is $17.37 and its two-hundred day moving average is $18.11.

Analysts Set New Price Targets

FLGT has been the subject of a number of recent analyst reports. StockNews.com raised Fulgent Genetics from a "sell" rating to a "hold" rating in a research report on Wednesday, March 5th. Piper Sandler decreased their target price on Fulgent Genetics from $22.00 to $16.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th.

Insider Activity

In other Fulgent Genetics news, CFO Paul Kim acquired 100,000 shares of Fulgent Genetics stock in a transaction dated Wednesday, March 5th. The stock was bought at an average cost of $15.96 per share, with a total value of $1,596,000.00. Following the completion of the transaction, the chief financial officer now owns 348,282 shares of the company's stock, valued at $5,558,580.72. The trade was a 40.28 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 31.76% of the stock is owned by company insiders.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.